Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized trial of TAS-303 in female stress urinary incontinence
jRCT2080225307Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stress urinary incontinence (SUI) comparing TAS-303 18 mg with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Aug 2020; status: completed.
02
Drugs
TAS-303
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on jRCT2080225307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225307.